Symbols / IMA Stock $5.66 -5.82% ImageneBio, Inc.

Healthcare • Biotechnology • United States • NCM
IMA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Kristin Yarema Ph.D.
Exch · Country NCM · United States
Market Cap 63.31M
Enterprise Value -69.07M
Income -52.40M
Sales 800.00K
FCF (ttm) -18.87M
Book/sh 11.91
Cash/sh 12.10
Employees 15
Insider 10d —
IPO Mar 26, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.68
PEG —
P/S 79.13
P/B 0.48
P/C —
EV/EBITDA 1.44
EV/Sales -86.33
Quick Ratio 12.16
Current Ratio 12.49
Debt/Eq 2.23
LT Debt/Eq —
EPS (ttm) -9.64
EPS next Y -3.37
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-12
Earnings (prior) 2025-11-12
ROA -35.86%
ROE -68.91%
ROIC —
Gross Margin 100.00%
Oper. Margin -60.56%
Profit Margin 0.00%
Shs Outstand 11.18M
Shs Float 6.26M
Insider Own 14.96%
Instit Own 50.32%
Short Float —
Short Ratio 0.64
Short Interest 387.03K
52W High 18.00
vs 52W High -68.56%
52W Low 3.94
vs 52W Low 43.65%
Beta —
Impl. Vol. —
Rel Volume 0.30
Avg Volume 364.29K
Volume 109.89K
Target (mean) $16.00
Tgt Median $16.00
Tgt Low $2.00
Tgt High $30.00
# Analysts 2
Recom None
Prev Close $6.01
Price $5.66
Change -5.82%
About

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$16.00
Mean price target
2. Current target
$5.66
Latest analyst target
3. DCF / Fair value
$-30.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.66
Low
$2.00
High
$30.00
Mean
$16.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-24 init Leerink Partners — → Outperform $30
News
RSS: Latest IMA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-16 YAREMA KRISTIN Chief Executive Officer — 85,400 $0.00 $0
2025-12-30 BUTLER ERIN Officer — 22,500 $0.00 $0
2025-12-24 SLATTERY JOSEPH P Director — 16,000 $5.99 $95,840
2025-07-28 MARANGO JOTIN Chief Financial Officer — 15,776 $0.00 $0
2025-07-25 STAMPACCHIA OTELLO Director — 267,556 $1.43 $382,605
2025-07-25 STAMPACCHIA OTELLO Director — 379 — —
2025-07-25 WANG JONATHAN JIAN Director — 1,115,005 $0.00 $0
2025-07-25 BONITA DAVID P. M.D. Director — 83,611 $1.43 $119,564
2025-07-25 BONITA DAVID P. M.D. Director — 379 — —
2025-07-25 ORBIMED ADVISORS, L.L.C. Director — 83,611 $1.43 $119,564
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.80
-77.14%
3.50
-56.04%
7.96
Operating Revenue
0.80
-77.14%
3.50
-56.04%
7.96
Operating Expense
49.25
+21.61%
40.50
+35.51%
29.89
Research And Development
28.52
-11.16%
32.11
+46.44%
21.93
Selling General And Administration
20.73
+147.00%
8.39
+5.40%
7.96
General And Administrative Expense
20.73
+147.00%
8.39
+5.40%
7.96
Salaries And Wages
5.02
0.00
-100.00%
2.60
Other Gand A
15.71
+87.16%
8.39
+5.40%
7.96
Total Expenses
49.25
+21.61%
40.50
+35.51%
29.89
Operating Income
-48.45
-30.95%
-37.00
-68.76%
-21.93
Total Operating Income As Reported
-48.45
-30.95%
-37.00
-68.76%
-21.93
EBITDA
-47.42
-33.67%
-35.47
-88.39%
-18.83
Normalized EBITDA
-47.42
-33.67%
-35.47
-88.39%
-18.83
Reconciled Depreciation
1.03
-32.31%
1.53
-50.69%
3.10
EBIT
-48.45
-30.95%
-37.00
-68.76%
-21.93
Net Income
-45.35
-24.01%
-36.57
-72.91%
-21.15
Pretax Income
-45.70
-25.01%
-36.55
-75.17%
-20.87
Net Non Operating Interest Income Expense
2.04
+444.12%
0.37
-68.68%
1.19
Net Interest Income
2.04
+444.12%
0.37
-68.68%
1.19
Interest Income Non Operating
—
0.37
-68.68%
1.19
Interest Income
—
0.37
-68.68%
1.19
Other Income Expense
0.72
+909.86%
0.07
+151.82%
-0.14
Other Non Operating Income Expenses
0.72
+909.86%
0.07
+151.82%
-0.14
Tax Provision
-0.35
-2792.31%
0.01
-95.36%
0.28
Tax Rate For Calcs
0.00
-96.67%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-45.35
-24.01%
-36.57
-72.91%
-21.15
Net Income From Continuing Operation Net Minority Interest
-45.35
-24.01%
-36.57
-72.91%
-21.15
Net Income From Continuing And Discontinued Operation
-45.35
-24.01%
-36.57
-72.91%
-21.15
Net Income Continuous Operations
-45.35
-24.01%
-36.57
-72.91%
-21.15
Normalized Income
-45.35
-24.01%
-36.57
-72.91%
-21.15
Net Income Common Stockholders
-52.40
-8.29%
-48.38
-51.02%
-32.04
Otherunder Preferred Stock Dividend
7.05
-40.37%
11.82
+8.50%
10.89
Diluted EPS
—
-4.33
-51.02%
-2.87
Basic EPS
—
-4.33
-51.02%
-2.87
Basic Average Shares
—
11.18
+0.00%
11.18
Diluted Average Shares
—
11.18
+0.00%
11.18
Diluted NI Availto Com Stockholders
-52.40
-8.29%
-48.38
-51.02%
-32.04
Average Dilution Earnings
—
-11.82
-8.50%
-10.89
Total Other Finance Cost
-2.04
-444.12%
-0.37
+68.68%
-1.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
152.98
+860.78%
15.92
-49.04%
31.25
Current Assets
140.29
+1025.18%
12.47
-51.86%
25.90
Cash Cash Equivalents And Short Term Investments
135.35
+1016.93%
12.12
-52.43%
25.47
Cash And Cash Equivalents
94.53
+680.10%
12.12
-20.91%
15.32
Other Short Term Investments
40.82
0.00
-100.00%
10.15
Receivables
1.30
+1461.45%
0.08
-62.78%
0.22
Other Receivables
1.30
+1461.45%
0.08
-62.78%
0.22
Prepaid Assets
3.64
+1264.42%
0.27
+30.88%
0.20
Total Non Current Assets
12.69
+267.34%
3.45
-35.39%
5.35
Net PPE
0.79
+42.34%
0.56
-87.04%
4.28
Gross PPE
0.79
-11.04%
0.89
-88.05%
7.43
Accumulated Depreciation
0.00
+100.00%
-0.33
+89.44%
-3.15
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.00
-100.00%
0.11
-8.80%
0.12
Other Properties
0.79
+44.42%
0.55
-86.36%
4.01
Leases
0.00
-100.00%
0.23
-93.12%
3.30
Investments And Advances
0.00
-100.00%
0.94
+0.00%
0.94
Non Current Deferred Assets
0.00
-100.00%
1.89
0.00
Non Current Prepaid Assets
4.88
+6969.57%
0.07
-43.90%
0.12
Total Liabilities Net Minority Interest
19.84
-88.76%
176.49
+12.16%
157.35
Current Liabilities
11.23
-34.72%
17.21
+81.26%
9.49
Payables And Accrued Expenses
6.08
-22.19%
7.82
-2.25%
8.00
Payables
1.44
-72.80%
5.29
-12.01%
6.01
Accounts Payable
1.44
-72.80%
5.29
-9.96%
5.88
Current Accrued Expenses
4.64
+83.67%
2.53
+27.28%
1.99
Pensionand Other Post Retirement Benefit Plans Current
2.89
+210.20%
0.93
-7.46%
1.01
Total Tax Payable
—
0.00
-100.00%
0.14
Current Debt And Capital Lease Obligation
2.26
-71.03%
7.81
+1768.18%
0.42
Current Debt
—
7.50
—
Current Capital Lease Obligation
2.26
+632.04%
0.31
-26.08%
0.42
Current Deferred Liabilities
0.00
-100.00%
0.65
+815.49%
0.07
Current Deferred Revenue
0.00
-100.00%
0.65
+815.49%
0.07
Total Non Current Liabilities Net Minority Interest
8.60
-94.60%
159.28
+7.72%
147.86
Long Term Debt And Capital Lease Obligation
0.71
+198.33%
0.24
-57.70%
0.56
Long Term Capital Lease Obligation
0.71
+198.33%
0.24
-57.70%
0.56
Tradeand Other Payables Non Current
0.00
—
—
Non Current Deferred Liabilities
—
0.00
-100.00%
0.07
Non Current Deferred Revenue
—
0.00
-100.00%
0.07
Other Non Current Liabilities
0.87
—
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
159.04
+8.03%
147.22
Stockholders Equity
133.14
+182.92%
-160.56
-27.32%
-126.11
Common Stock Equity
133.14
+174.16%
-179.53
-23.75%
-145.07
Capital Stock
0.01
-99.94%
18.97
-0.05%
18.98
Common Stock
0.01
+1000.00%
0.00
-90.00%
0.01
Preferred Stock
0.00
-100.00%
18.97
+0.00%
18.97
Share Issued
11.18
0.00%
11.18
+0.00%
11.18
Ordinary Shares Number
11.18
0.00%
11.18
+0.00%
11.18
Additional Paid In Capital
363.09
+16725.49%
2.16
0.00
Retained Earnings
-230.05
-27.88%
-179.90
-25.51%
-143.33
Gains Losses Not Affecting Retained Earnings
0.09
+104.86%
-1.79
-2.17%
-1.75
Total Equity Gross Minority Interest
133.14
+182.92%
-160.56
-27.32%
-126.11
Total Capitalization
133.14
+182.92%
-160.56
-27.32%
-126.11
Working Capital
129.05
+2822.08%
-4.74
-128.90%
16.41
Invested Capital
133.14
+177.39%
-172.03
-18.58%
-145.07
Total Debt
2.98
-63.03%
8.05
+718.72%
0.98
Capital Lease Obligations
2.98
+442.88%
0.55
-44.25%
0.98
Net Tangible Assets
133.14
+182.92%
-160.56
-27.32%
-126.11
Tangible Book Value
133.14
+174.16%
-179.53
-23.75%
-145.07
Available For Sale Securities
—
0.94
+0.00%
0.94
Dueto Related Parties Non Current
7.02
—
—
Interest Payable
—
1.29
0.00
Investmentin Financial Assets
0.00
-100.00%
0.94
+0.00%
0.94
Line Of Credit
0.00
-100.00%
7.50
0.00
Non Current Note Receivables
7.02
0.00
—
Preferred Stock Equity
—
18.97
+0.00%
18.97
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-47.84
-124.42%
-21.32
-16.93%
-18.23
Cash Flow From Continuing Operating Activities
-47.84
-124.42%
-21.32
-16.93%
-18.23
Net Income From Continuing Operations
-45.35
-24.01%
-36.57
-72.91%
-21.15
Depreciation Amortization Depletion
1.03
-32.31%
1.53
-50.69%
3.10
Depreciation
1.03
-32.31%
1.53
-50.69%
3.10
Depreciation And Amortization
1.03
-32.31%
1.53
-50.69%
3.10
Other Non Cash Items
0.34
-97.57%
13.96
+1582.48%
-0.94
Stock Based Compensation
15.39
0.00
—
Operating Gains Losses
—
1.27
+127300.00%
0.00
Unrealized Gain Loss On Investment Securities
—
0.00
+100.00%
-0.14
Gain Loss On Sale Of PPE
0.00
-100.00%
1.27
+127300.00%
0.00
Change In Working Capital
-19.19
-1165.70%
-1.52
-268.82%
0.90
Change In Prepaid Assets
-3.96
-5038.96%
-0.08
-177.00%
0.10
Change In Payables And Accrued Expense
-11.92
-655.20%
-1.58
-199.50%
1.59
Change In Accrued Expense
-9.10
-762.27%
-1.05
+54.13%
-2.30
Change In Payable
-2.82
-439.20%
-0.52
-113.46%
3.89
Change In Account Payable
-2.82
-439.20%
-0.52
-113.46%
3.89
Change In Other Working Capital
-0.65
-227.45%
0.51
+466.91%
-0.14
Change In Other Current Assets
-1.21
-2331.48%
0.05
0.00
Change In Other Current Liabilities
-1.46
-243.29%
-0.42
+34.51%
-0.65
Investing Cash Flow
-5.81
-152.27%
11.12
+206.40%
-10.45
Cash Flow From Continuing Investing Activities
-5.81
-152.27%
11.12
+206.40%
-10.45
Net PPE Purchase And Sale
0.00
-100.00%
0.97
+420.79%
-0.30
Purchase Of PPE
—
0.00
+100.00%
-0.30
Sale Of PPE
0.00
-100.00%
0.97
+48500.00%
0.00
Capital Expenditure
—
—
-0.30
Net Investment Purchase And Sale
-0.60
-105.90%
10.15
+200.00%
-10.15
Purchase Of Investment
-10.40
0.00
+100.00%
-20.15
Sale Of Investment
9.80
-3.47%
10.15
+1.51%
10.00
Financing Cash Flow
135.47
+1861.60%
6.91
+4504.00%
0.15
Cash Flow From Continuing Financing Activities
135.47
+1861.60%
6.91
+4504.00%
0.15
Net Issuance Payments Of Debt
15.00
+100.00%
7.50
0.00
Issuance Of Debt
15.00
+100.00%
7.50
0.00
Short Term Debt Issuance
15.00
+100.00%
7.50
0.00
Net Short Term Debt Issuance
15.00
+100.00%
7.50
0.00
Net Common Stock Issuance
71.13
0.00
—
Proceeds From Stock Option Exercised
0.04
0.00
-100.00%
0.15
Net Other Financing Charges
49.29
+8398.48%
-0.59
—
Changes In Cash
81.81
+2586.63%
-3.29
+88.47%
-28.54
Effect Of Exchange Rate Changes
0.60
+594.25%
0.09
+158.78%
-0.15
Beginning Cash Position
12.12
-20.91%
15.32
-65.18%
44.01
End Cash Position
94.53
+680.10%
12.12
-20.91%
15.32
Free Cash Flow
-47.84
-124.42%
-21.32
-15.00%
-18.54
Income Tax Paid Supplemental Data
0.02
-89.59%
0.22
+87.29%
0.12
Amortization Of Securities
-0.07
0.00
—
Common Stock Issuance
71.13
0.00
—
Dividends Received CFI
-5.21
0.00
—
Issuance Of Capital Stock
71.13
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category